
Leqembi approved as first treatment to slow early Alzheimer’s progression
European Commission grants authorisation for Eisai and Biogen therapy The European Commission has granted marketing authorisation for Leqembi (lecanemab), making it the first therapy in the EU to slow the progression of early Alzheimer’s disease. Lecanemab …